What We Do
Why We Exist
What We Are
What We Aren’t
The Origin
A Discovery in the Lab and Real World
In 2011, Matthew Halpert, Ph.D., joined a research team of cancer immunologists studying and
developing a revolutionary
approach to cancer treatment at Texas Medical Center. Dr. Halpert witnessed firsthand the
powerful effects of this
unique Dendritic Cell Treatment both in the laboratory and in real-world case studies.
This
work has resulted in
multiple, active FDA clinical trials studying the efficacy of this treatment. While this
represents significant
potential for cancer treatment, it did not help patients who did not qualify for the clinical
trials.
The Future of Immunotherapy, Today
Unfortunately, many of these cancer patients who would note qualify for clinical trials cannot
wait for treatment.
Immunocine was founded to provide them an alternative.
An alternative treatment that they can truly believe in. An alternative treatment that is both
backed in science and
real-world results.
One Treatment, Over 20 Cancer Types
Unlike many alternative cancer centers, Immunocine only provides one treatment, a completely unique Dendritic Cell Immunotherapy. It is a treatment that is unique to each patient and has worked across a variety of cancer types and stages. From Advanced Triple Negative Breast Cancer to Metastatic Prostate Cancer, our patients have seen incredible results despite being deemed refractory or incurable by their physicians.
Who We Are
Jay Hartenbach, MEM
CEO
Matthew Halpert, PhD
President
Luis Ferbeyre, MD
Chief Medical Officer
Susana Hernandez, MSc
Director of Cell Therapy
Our team of specialists have a vast array of experience in Cancer, Immunology, and Cell Therapy.
Meet the Full TeamWhere We Are
Welcome to Paradise: Cancún
Until our treatment completes FDA Clinical Trials, it is only available overseas. Fortunately,
Mexico offers broader
treatment options for patients who don’t have time to wait.
For many, Medical Tourism is the best option to gain access to treatments that aren’t approved
yet or to find lower-cost
alternatives. Until now, our IDCT treatment has only been accessible to those participating in
clinical trials.
State-of-the-Art Facilities & Service
Our cGMP, ISO-certified facility allows us to manufacture every treatment to ensure patient success and safety. All of our treatments are administered at the Galenia Hospital, which is internationally accredited and one of the most advanced hospitals in Mexico. Cancún and its sophisticated healthcare infrastructure allow our team to provide this treatment and superior care simultaneously.
Our Dendritic Cell Treatment initiates a complete Immune Response against your
cancer cells.
This top-down approach avoids the unspecific and ineffective targeting of other
Immunotherapies.
Our Dendritic Cell Treatment does not introduce any foreign compounds or genetically
modified cells into the body.
By using your body’s own cells, our treatment significantly reduces the risk of side
effects.
Our Dendritic Cell Treatment fully activates the Immune System and therefore
continues after patients have received their last treatment.
This Immunological Memory can make it much harder for the cancer to return.
